VRXA (Veraxa Biotech Holding AG) Return-on-Tangible-Asset: -949.97% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRXA Veraxa Biotech Holding AG VRXA
6 GF Score
Price $1.77
! 2 Warning Signs
View Full Analysis

What is Veraxa Biotech Holding AG Return-on-Tangible-Asset?

Veraxa Biotech Holding AG VRXA -10.66% 6 Return-on-Tangible-Asset is -949.97% as of Dec. 2025. GuruFocus rates VRXA with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 1,415 Biotechnology companies, Veraxa Biotech Holding AG ranks worse than 98.87% on this metric.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Veraxa Biotech Holding AG's annualized Net Income for the quarter that ended in Dec. 2025 was $-75.28 Mil. Veraxa Biotech Holding AG's average total tangible assets for the quarter that ended in Dec. 2025 was $7.92 Mil. Therefore, Veraxa Biotech Holding AG's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was -949.97%.

The historical rank and industry rank for Veraxa Biotech Holding AG's Return-on-Tangible-Asset or its related term are showing as below:

VRXA' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -980.02   Med: -245.91   Max: -118.06
Current: -980.02

During the past 3 years, Veraxa Biotech Holding AG's highest Return-on-Tangible-Asset was -118.06%. The lowest was -980.02%. And the median was -245.91%.

VRXA's Return-on-Tangible-Asset is ranked worse than
98.87% of 1415 companies
in the Biotechnology industry
Industry Median: -35.38 vs VRXA: -980.02

Veraxa Biotech Holding AG  (NAS:VRXA) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Veraxa Biotech Holding AG Return-on-Tangible-Asset Related Terms


Veraxa Biotech Holding AG Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for Veraxa Biotech Holding AG's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veraxa Biotech Holding AG Return-on-Tangible-Asset Chart

Veraxa Biotech Holding AG Annual Data
Trend Dec23 Dec24 Dec25
Return-on-Tangible-Asset
-118.06 -245.91 -979.62

Veraxa Biotech Holding AG Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Return-on-Tangible-Asset 0.00 -135.69 -434.19 -1,017.71 -949.97

VRXA vs TTRX, IRD, IFRX: Return-on-Tangible-Asset Comparison

For the Biotechnology subindustry, Veraxa Biotech Holding AG's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veraxa Biotech Holding AG Return-on-Tangible-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Veraxa Biotech Holding AG's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Veraxa Biotech Holding AG's Return-on-Tangible-Asset falls into.


VRXA
6GF Score
Veraxa Biotech Holding AG VRXA
Return-on-Tangible-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veraxa Biotech Holding AG Return-on-Tangible-Asset Calculation

Veraxa Biotech Holding AG's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-83.591/( (9.458+7.608)/ 2 )
=-83.591/8.533
=-979.62 %

Veraxa Biotech Holding AG's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-75.28/( (8.241+7.608)/ 2 )
=-75.28/7.9245
=-949.97 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.

What does a Return-on-Tangible-Asset of -949.97% mean?
Veraxa Biotech Holding AG (VRXA) has a Return-on-Tangible-Asset of -949.97% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Veraxa Biotech Holding AG and its competitors. According to the industry distribution chart, Veraxa Biotech Holding AG ranks #1399 out of 1415 companies in the Biotechnology industry, placing it in the top 98.9%.
Is Veraxa Biotech Holding AG's Return-on-Tangible-Asset too high?
Veraxa Biotech Holding AG's current Return-on-Tangible-Asset is -949.97%. Based on the distribution chart, Veraxa Biotech Holding AG ranks #1399 out of 1415 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Veraxa Biotech Holding AG has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Veraxa Biotech Holding AG's Return-on-Tangible-Asset compare to TTRX and IRD?
According to the Biotechnology industry distribution chart, Veraxa Biotech Holding AG ranks #1399 out of 1415 companies for Return-on-Tangible-Asset. This places Veraxa Biotech Holding AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Veraxa Biotech Holding AG and its competitors. Veraxa Biotech Holding AG's current Return-on-Tangible-Asset is -949.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veraxa Biotech Holding AG stock overvalued right now?
Veraxa Biotech Holding AG (VRXA) has a current Return-on-Tangible-Asset of -949.97%. The current Return-on-Tangible-Asset is -949.97%. Veraxa Biotech Holding AG's overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Veraxa Biotech Holding AG (VRXA), the current Return-on-Tangible-Asset is -949.97% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veraxa Biotech Holding AG Business Description

Other Exchanges J8L0:Germany
Address Talacker 35, Zurich, CHE, 8001
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
6GF Score

Get the complete analysis for VRXA

Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.77
Price